2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1)
The summary for the 2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1): Purpose The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals (small molecules) or biologics. Biologics include medicinal products such as vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the pharmacotherapy of one or various disorders. Applications may also focus on the specific symptoms of the disorder such as withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available for other indications, or new combinations of existing medications, which may be promising candidates for the treatment of diseases of addiction is within the scope of this FOA. The 2010 Translational Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-10-095. Pre-applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2010 Avant-Garde awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Pre-applications for 2010 Translational Avant-Garde Awards were encouraged under PAR-10-095. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIDA intends to commit $2 million for 2-3 awards in fiscal 2010.
|Federal Grant Title:||2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-DA-10-013|
|Type of Funding:||Grant|
|CFDA Descriptions:||Drug Abuse and Addiction Research Programs|
|Current Application Deadline:||Jul 02, 2010|
|Original Application Deadline:||Jul 02, 2010|
|Posted Date:||Jan 26, 2010|
|Creation Date:||Jan 26, 2010|
|Archive Date:||Aug 02, 2010|
|Total Program Funding:||$2,000,000|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, An...
- • Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
- • Research Networks for the Study of Recovery Support Services for Persons Treated with Medi...
- • The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowe...
- • The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...